Given that TLR4 activation drives pathological inflammatory reactions and is implicated in the development of various diseases, including Alzheimer’s disease, non-alcoholic fatty liver disease, cryopyrin-associated periodic syndromes, atherosclerosis, type 2 diabetes, and asthma, inhibiting TLR4 activation holds promise as a strategy for developing new treatments for inflammatory diseases (25–28). This evidence concerns the gene TLR4 and early-onset autosomal dominant Alzheimer disease.